Inspirna is a privately-held clinical-stage biopharmaceutical company on a mission to develop novel cancer medicines inspired by RNA biology. With a focus on addressing difficult-to-treat cancers, their experienced team of drug developers is committed to generating innovative medicines. Inspirna is at the forefront of cancer research, developing first-in-class drugs that specifically target critical cancer drivers.

At the heart of their success is Inspirna's pioneering discovery platform, RNA-DRIVEr™. This platform, exclusively licensed to Inspirna, was developed by their founding scientists at Rockefeller University. It enables the development of both small molecule and biologic therapeutics, revolutionizing the field of oncology drug development.

By leveraging their expertise and cutting-edge technology, Inspirna is dedicated to bringing effective treatments to high unmet need oncology settings. With a focus on precision and patient-centric care, Inspirna is transforming the landscape of cancer treatment. For more information about Inspirna, their research, and their commitment to improving patients' lives, visit their website or contact them directly